Table 3.
FVP group (n = 32) | LPV/RTV group (n = 31) | p | |
---|---|---|---|
Primary outcomes (day 7) | |||
SARS‐CoV‐2 clearance | 10 (31.3) | 5 (16.1) | 0.237 |
SpO2 | 93.0 (88.5–96.0) | 93.0 (88.2–94.0) | 0.628 |
Temperature | 36.7 (36.6–37.1) | 37.0 (36.8–37.0) | 0.066 |
Respiratory rate | 20.0 (18.0–28.5) | 22.5 (20.0–27.5) | 0.108 |
Secondary outcomes | |||
LOS in hospital, days | 6.0 (5.0–11.0) | 8.0 (5.5–12.5) | 0.140 |
Admission in ICU | 4 (12.5) | 6 (19.4) | 0.509 |
In‐hospital mortality | |||
By Day 14 | 2 (6.3) | 6 (19.4) | 0.148 |
By Day 7 | 1 (3.1) | 1 (3.2) | 0.999 |
Note: Values were expressed as median (IQR) or n (%).
Comparison between groups was performed using the Mann–Whitney U‐test or the Fisher's exact test.
Data were collected after 7 or 14 days of randomization.
Abbreviations: FVP, favipiravir; LOS, length of stay; LPV/RTV, lopinavir/ritonavir, SpO2, peripheral capillary oxygen saturation.